UK High Court rules AstraZeneca's Seroquel XR formulation patent 'invalid'
This article was originally published in Scrip
Executive Summary
The UK High Court has become first to decide that AstraZeneca's formulation patent protecting its atypical antipsychotic drug, Seroquel XR (quetiapine fumarate), is invalid for obviousness.